The 3 Best Stocks to Invest $1,000 in Right Now

Numerous factors are affecting the stock market right now. However, many long-term opportunities remain. Some stocks benefit from current trends, whether they be rising spot gold prices or accelerating adoption of generative artificial intelligence (AI).

There are also stocks benefiting from trends unaffected by the macroeconomic and geopolitical backdrop. While these stocks are not necessarily immune to near-term market volatility, buying them today could prove very profitable in the long run.

Three stocks that come to mind are Brookfield Corporation (NYSE: BN), SSR Mining (NASDAQ: SSRM), and Teva Pharmaceuticals (NYSE: TEVA). Even if you only have $1,000 today to put toward a long-term portfolio, each stock is a great choice.

Image source: Getty Images.

Brookfield is an undervalued compounding machine

Canada-based holding company Brookfield Corporation may seem complicated.In addition to its majority stake in its well-known Brookfield Asset Management (NYSE: BAM) subsidiary, Brookfield also holds interests in a variety of public and privately held investment vehicles managed by the asset management unit.

Brookfield has also vastly expanded its insurance operations, focusing on profiting from the long-term investment of its insurance assets, similar to Berkshire Hathaway's objective when it comes to owning insurance companies . For years, Brookfield's management has noted that the company trades at a discount to the underlying value of its holdings.

This valuation discount persists and could continue to do so. Even so, as management also anticipates more than 20% earnings growth over the next five years, such growth could help close the valuation gap, resulting in strong price appreciation.

SSR Mining could thrive in uncertain times

As geopolitical tensions escalate, spot gold prices spiked yet again. That's good news for those holding physical gold in their portfolios, but for those owning precious metals stocks, higher gold prices could have an outsized impact on their investments.

That's the bull case for SSR Mining. The production-stage gold mining company's fiscal performance improved substantially last year, thanks to gold surging from $3,000 to over $5,000 per ounce. In 2025, this high-double-digit increase in gold prices resulted in more than a sevenfold adjusted earnings growth

Following the latest gold spike, SSR's stock price has hit new highs. However, don't assume shares have topped out. Multiple factors point to gold remaining at elevated prices, if not moving higher. If high gold prices are here to stay, SSR Mining could rise on both higher earnings and valuation expansion.

Currently, the stock trades for less than 9 times forward earnings, while other mining stocks such as Barrick Mining trade at forward multiples in the mid-teens .

Teva's transformation is still unfolding

Israel-based Teva Pharmaceuticals has been a generic drugmaker. In recent years, the company has pivoted to become a branded pharmaceutical company, especially in specialty drugs and treatments.

Teva's generics business is experiencing little to no growth, but its branded drug business is growing at a mid-double-digit clip. As more of the company's drug pipeline advances through clinical trials and regulatory approval, Teva should remain positioned to sustain steady sales and profitability growth.

This growth, along with the move from generic to branded products, could lead to a further reassessing the value of shares. Teva currently trades for 12.5 times forward earnings, but a mid-teens forward multiple could be warranted, given the valuation of other faster-growing pharmaceutical stocks.

Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Berkshire Hathaway, Brookfield, Brookfield Asset Management, and Brookfield Corporation. The Motley Fool has a disclosure policy.